phrykt

BioXcel Therapeutics, Inc. (BTAIQ): who owns it and who trades it

As of Oct 30, 2026, BTAIQ insiders reported 3 open-market sales worth $35.7K and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Vimal Mehta (CEO), with $21.2K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, BTAIQ insiders reported $0 of open-market purchases and $35.7K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$35.7K
3 trades, 3 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
May 20, 2026
Filed May 22, 2026

Purchases and sales by month

$35.7K$35.7KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 20, 2026Frank YoccaChief Scientific OfficerSale plan6,845$1.09$7.5KForm 4
May 20, 2026Javier RodriguezSee RemarksSale plan6,560$1.08$7.1KForm 4
May 20, 2026Vimal MehtaCEOSale plan19,419$1.09$21.2KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Vimal MehtaCEO and President, Director–$21.2KMay 20, 2026
Frank YoccaChief Scientific Officer–$7.5KMay 20, 2026
Javier RodriguezSee Remarks–$7.1KMay 20, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BTAIQ short interest

Low short interest. 4.5% of BTAIQ shares are sold short: about 1 share in 22. Over the last 4 reports the number of shares short went down 54%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.42M BTAIQ shares were sold short, 4.5% of the shares outstanding, down 13.5% from the report before. At the average daily volume of 432,308 shares, buying them all back would take about 3.3 trading days (days to cover).

Shares short, % of all shares

4.54%Sep 15Oct 3010.6%

Days to cover

3.3Sep 15Oct 304.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.42M4.54%-13%432,3083.3
Oct 15, 20261.64M5.24%-17%440,0683.7
Sep 30, 20261.97M6.28%-36%1.20M1.6
Sep 15, 20263.08M9.85%-50%28.10M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

BioXcel Therapeutics company events

BioXcel Therapeutics filed 18 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing, bankruptcy). The latest was on Oct 30, 2026.

  1. Oct 30, 2026LeadershipIn connection with the Sale and the wind-down of the Company’s affairs, the board of directors of the Company terminated Vimal Mehta, Ph.D., the Company’s Chief Executive Officer and President, Richard Steinhart, the Company’s Senior Vice President and Chief Financial Officer, Frank Yocca, Ph.D.… Filing
  2. Sep 1, 2026ListingThe Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC that Nasdaq had determined to delist the Company’s common stock, par value $0.001 per share in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM 5101-1 as a result of the Company’s commencement… Filing
  3. Aug 28, 2026BankruptcyOf this Current Report on Form 8-K is incorporated herein by reference. Filing
  4. Aug 25, 2026AgreementBioXcel Therapeutics, Inc. entered into the Fourteenth Amendment to Credit Agreement and Guaranty, which amended the Credit Agreement and Guaranty, dated April 19, 2022, as amended, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as… Filing
  5. Aug 24, 2026AgreementBioXcel Therapeutics, Inc. entered into the Thirteenth Amendment to Credit Agreement and Guaranty, which amended the Credit Agreement and Guaranty, dated April 19, 2022, as amended, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as… Filing
  6. Aug 11, 2026AgreementBioXcel Therapeutics, Inc. entered into the Twelfth Amendment to Credit Agreement and Guaranty and First Amendment to Security Agreement, which amended the Credit Agreement and Guaranty, dated April 19, 2022, as amended, by and among the Company, as the borrower, certain subsidiaries of the Company… Filing
  7. Aug 3, 2026AgreementBioXcel Therapeutics, Inc. entered into the Eleventh Amendment to Credit Agreement and Guaranty, which amended the Credit Agreement and Guaranty, dated April 19, 2022, as amended, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as… Filing
  8. Jul 6, 2026AgreementBioXcel Therapeutics, Inc. entered into the Tenth Amendment to Credit Agreement and Guaranty, which amended the Credit Agreement and Guaranty, dated April 19, 2022, as amended, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as… Filing
  9. May 15, 2026ResultsReleased financial results. Filing
  10. Apr 17, 2026SharesSold new shares outside a public offering. Filing
  11. Apr 1, 2026AnnouncementBioXcel Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI . The FDA has assigned a… Filing
  12. Mar 27, 2026ResultsReleased financial results. Filing
  13. Mar 11, 2026AgreementBioXcel Therapeutics, Inc. entered into a securities purchase agreement with the purchaser named therein. Filing
  14. Feb 12, 2026AnnouncementBioXcel Therapeutics, Inc. announced the completion of an updated market opportunity assessment for IGALMI® for acute agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting, informed by results from the SERENITY At-Home clinical study. Filing
  15. Feb 6, 2026LeadershipBioXcel Therapeutics, Inc., following the Company’s recent submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI… Filing
  16. Jan 20, 2026AnnouncementBioXcel Therapeutics, Inc. announced the submission on January 14, 2026 of a supplemental New Drug Application to the U.S. Food and Drug Administration for IGALMI® in the at-home use setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia. Filing
  17. Jan 12, 2026AnnouncementBioXcel Therapeutics, Inc. announced that Mark Pavao is joining the Company as Interim Chief Commercial Officer to support the potential launch of IGALMI in the at-home setting. Filing
  18. Dec 15, 2025VoteReported shareholder vote results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

BioXcel Therapeutics financials

Famous investors that hold BTAIQ

1 of the 50 well-known investors we track reported holding BTAIQ in their latest 13F filing. The largest position is Howard Marks's, worth $1.9M.

FundQuarterSharesValueOf portfolioChange
Howard Marks · Oaktree Capital ManagementQ2 20261.38M$1.9M0.1%+472%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about BioXcel Therapeutics, Inc. (BTAIQ) stock

Are BTAIQ insiders buying or selling?

In the last 12 months, BTAIQ insiders reported no open-market purchases and 3 sales worth $35.7K. The latest trade was on May 20, 2026. See every trade.

What is the short interest in BTAIQ?

As of Oct 30, 2026, 1.42M BTAIQ shares were sold short, 4.5% of the shares outstanding, down 13.5% from the report before. At the average daily volume of 432,308 shares, buying them all back would take about 3.3 trading days (days to cover). See the history.

Which famous investors hold BTAIQ?

1 of the 50 well-known investors we track reported BTAIQ in their latest 13F filing, including Howard Marks. The largest position is worth $1.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.